Imperial College London
Alternate

ProfessorDianaBilton

Faculty of Medicine, National Heart & Lung Institute

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)7801 067 057diana.bilton

 
 
//

Location

 

Fulham RoadRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Higgins:2020:10.1007/s41030-020-00115-8,
author = {Higgins, M and Volkova, N and Moy, K and Marshall, BC and Bilton, D},
doi = {10.1007/s41030-020-00115-8},
journal = {Pulmonary Therapy},
pages = {141--149},
title = {Real-world outcomes among patients with cystic fibrosis treated with ivacaftor: 2012-2016 experience.},
url = {http://dx.doi.org/10.1007/s41030-020-00115-8},
volume = {6},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: In this long-term, postapproval, observational study, data from the US Cystic Fibrosis Foundation Patient Registry and the UK Cystic Fibrosis Registry were used to evaluate the impact of ivacaftor treatment on cystic fibrosis (CF) by comparing outcomes in ivacaftor-treated patients with those in matched untreated comparator patients. Registry data from up to 5 years of ivacaftor availability in the US and up to 4 years of availability in the UK were evaluated. METHODS: Starting in the first year of ivacaftor availability, ivacaftor-treated patients in each registry were matched 1:5 to comparator patients who never received ivacaftor. Clinical endpoints were evaluated in annual cross-sectional safety analyses. The key endpoints were death, organ transplants, pulmonary exacerbation, and hospitalization. Relative risks and 95% CIs were calculated to compare the ivacaftor and comparator cohorts in each registry. RESULTS: Here, we report the complete and final results of the annual cross-sectional safety analyses across the duration of the study, with up to 5 years of follow-up. Data show a pattern of lower risk of death, transplant, pulmonary exacerbation, and hospitalization among ivacaftor-treated patients in both registries. CONCLUSIONS: Ivacaftor-treated patients had consistently favorable clinical outcomes relative to untreated comparators, and no new safety concerns were identified. While general limitations of observational research apply, these findings support disease modification by CF transmembrane conductance regulator (CFTR) modulator therapy with ivacaftor. Future research of novel CFTR modulators will need to explore alternative methods for comparator selection for evaluation of clinical data given the evolving landscape of CF treatment.
AU  - Higgins,M
AU  - Volkova,N
AU  - Moy,K
AU  - Marshall,BC
AU  - Bilton,D
DO  - 10.1007/s41030-020-00115-8
EP  - 149
PY  - 2020///
SN  - 2364-1746
SP  - 141
TI  - Real-world outcomes among patients with cystic fibrosis treated with ivacaftor: 2012-2016 experience.
T2  - Pulmonary Therapy
UR  - http://dx.doi.org/10.1007/s41030-020-00115-8
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32304091
UR  - https://link.springer.com/article/10.1007%2Fs41030-020-00115-8
UR  - http://hdl.handle.net/10044/1/89933
VL  - 6
ER  -
Download